Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells
Open Access
- 27 July 2026
- journal article
- research article
- Published by MDPI AG in Non-Coding RNA
- Vol. 12 (4) , 26
Abstract
Background/Objectives: Recent advances in immunotherapy have revolutionized cancer treatment, as exemplified by multiple monoclonal antibodies against programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1). Nevertheless, immunotherapeutic antibodies exhibit certain limitations, which drives the development of alternative approaches, such as small interfering RNA (siRNA)-based therapeutics. The aim of this study was to design and produce new biological PD-L1 siRNA (BioRNA/PD-L1-siRNA) molecules and further define their immunotherapeutic efficacy against non-small cell lung cancer (NSCLC) in vitro. Methods: A novel RNA molecular bioengineering platform was employed to produce new BioRNA/PD-L1-siRNA agents. The functions of BioRNA/PD-L1-siRNAs were determined by quantitative PCR, Western blot, immunofluorescence confocal imaging, flow cytometry, and PD-1/PD-L1 blockade assays in human NSCLC cells, alone and co-cultured with human peripheral blood mononuclear cells (PBMCs). Results: After heterologous overexpression and purification of five BioRNA molecules, one siRNA named BioRNA/PD-L1-siRNA-1 was identified as the most effective to selectively suppress human PD-L1 mRNA and protein levels in H460 and H1975 cells. Disruption of PD-1/PD-L1 interactions by BioRNA/PD-L1-siRNA-1 was further demonstrated via a PD-1/PD-L1 blockade bioassay. In addition, the immunomodulatory effectiveness of BioRNA/PD-L1-siRNA-1 was established in co-culture models, as indicated by the induction of T-cell and natural killer cell populations and an increase in specific cytokines and cytotoxic granules, and subsequent enhancement of apoptosis and greater inhibition of NSCLC cell viability. Conclusions: Overall, these findings demonstrate the potential of bioengineered PD-L1 siRNA entities for NSCLC immunotherapy.Keywords
Funding Information
- National Institute of General Medical Sciences (R35GM140835)
- National Cancer Institute (R01CA225958)
- National Cancer Institute (R01CA291771)
- National Cancer Institute (P30CA093373)
- National Institutes of Health
- UC Davis Comprehensive Cancer Center Support Grant
This publication has 79 references indexed in Scilit:
- Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1ChemMedChem, 2026
- Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 ImmunotherapyChronic Diseases and Translational Medicine, 2025
- The role of the tumour microenvironment in lung cancer and its therapeutic implicationsMedical Oncology, 2025
- Lung cancer statistics, 2023Cancer, 2024
- Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsJAMA Network Open, 2024
- Chemoresistance Mechanisms in Non-Small Cell Lung Cancer—Opportunities for Drug RepurposingApplied Biochemistry and Biotechnology, 2023
- EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysisCancer Immunology, Immunotherapy, 2021
- Mechanisms of resistance to chemotherapy in non-small cell lung cancerArchives of Pharmacal Research, 2021
- The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancerJournal of Cancer Research and Clinical Oncology, 2019
- KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinomaCancer Immunology, Immunotherapy, 2017